Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China
Hua Medicine (the"Company", Stock Code: 2552.HK), a global innovative drug research and development company focused on the novel therapies for the treatment of Type 2 Diabetes (“T2D”), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2020 (the “Reporting Period”).
Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes.
Hua Medicine (the"Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301), the first Phase III trial with dorzagliatin.
Hua Medicine (the"Company", Stock Code: 2552. HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, announced post-analysis results from dorzagliatin’s 24-week monotherapy trial SEED, (also known as HMM0301).
Hua Medicine (the"Company", Stock Code: 2552. HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announces that post-analysis data from dorzagliatin’s monotherapy clinical trial, a dual-acting glucokinase activator (GKA) ...
Hua Medicine (the"Company", Stock Code: 2552. HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, is pleased to announce that the Company has been officially included as a constituent stock of the MSCI Hong Kong Micro Cap Index. The relevant change has been implemented as of the close of May 29, 2020.
Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112.
Hua Medicine (the"Company", Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019. For the year ended December 31, 2019, the Company incurred approximately RMB468.5 million in total expenses, of which approximately RMB 321.9 million was research and development expenses. As of December 31, 2019, the Company’s cash position was approximately RMB 1,105.6 million.